Lung cancer combo shows promise in slowing tumor growth

NCT ID NCT03909334

Ongoing Disease control Sponsor: Xiuning Le Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding ramucirumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their disease worsening. About 160 patients will receive either the combination or osimertinib alone. The study aims to see if the combo improves progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (Tagrisso) and ramucirumab (Cyramza)
What this could lead to: If successful, this combination could delay cancer progression longer than osimertinib alone, offering a new first-line option for EGFR-mutant lung cancer.
What could go wrong: This is a mid-stage trial with 160 participants, so results may not confirm benefit. Adding ramucirumab also raises risks like high blood pressure, bleeding, or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER EGFR GENE MUTATION METASTATIC CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Columbia University Irving Medical Center

New York, New York, 10032, United States
Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
Georgetown University

Washington D.C., District of Columbia, 20057, United States
Indiana Univesity Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
New York University Cancer Center

New York, New York, 10016, United States
Northwestern University Feinberg School of Medicine

Chicago, Illinois, 60611, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
Summit Medical Group, PA

Berkeley Heights, New Jersey, 07922, United States
University of Virginia Health System

Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.